Tag: biologics patent cliff
Europe vs US Biosimilar Markets: A 2026 Comparison
Compare the mature European biosimilar market with the rapidly accelerating US sector. Explore regulatory shifts, the $232B patent cliff, and why 2026 is a turning point for biologics.
Read more